Clinical Trials

Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO

NCT04267848

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

NCT02194738

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy

NCT04600336

N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

NCT00887146

NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults

NCT99999999

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

NCT03053193

Eliminating Breast Cancer Surgery in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579

External Beam Radiation to Eliminate Nominal Metastatic Disease (EXTEND): A Randomized Phase II Basket Trial Assessing the Efficacy of Upfront Local Consolidative Therapy (LCT) for Oligometastatic Disease (2018-0349)

NCT03599765

FLEX: Liquid Biopsy for Breast Cancer, a Pilot Study

NCT03053193

Genomics in Oncology: Clinical Outcomes and Determinants

NCT99999999

The Spiration IBV Valve System

NCT99999999

Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

NCT04397185

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

NCT04264702

EF-32: Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

NCT04471844

Inflammatory Breast Cancer (IBC) Registry

NCT00477100

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy

NCT04622319

A randomized study of head and neck radiotherapy with or without customized 3D printed oral stents

NCT04870762

Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)

NCT04739072

A Randomized Open-Label Phase III Study of Sacituzumab Govitecan versus Treatment of Physician s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer

NCT04527991

A Phase III, Open-Label, Multicenter,Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large BCell Lymphoma

NCT04408638

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

NCT04384484

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for he Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

NCT04895358

BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO)

NCT04761783

Stereotactic radiosurgery (SRS) as definitive management for a limited number of small cell lung cancer (SCLC) brain metastasis

NCT04516070

A Multicenter, Randomized, Double-Blind Phase 3 study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma not Previously Treated with PD-1 or PD-L1 Inhibitors

NCT04674683

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

NCT04762069

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

NCT04961996

Shortening Adjuvant PHoton IRradiation (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer

NCT02912312

A Phase III, Randomized Double-Blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously untreated Patients with Acute Myeloid Leukemia Who are ineligible for Intensive Chemotherapy

NCT05079230

PHASE 1 OPEN LABEL ASCENDING DOSE STUDY TO ASSESS THE FEASIBILITY AND SAFETY OF INTERMITTENT INFUSIONS OF MTX110 ADMINISTERED BY CONVECTION-ENHANCED DELIVERY (CED) AS A MONOTHERAPY OR IN COMBINATION WITH LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) (MAGIC-G1 STUDY)

NCT05324501

A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

NCT04657081

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

NCT05267106

Financial Toxicity in Diverse Cancer Populations and Care Settings

A Prospective, Multi-center, Randomized, Double-arm Trial to Determine the Impact of the SELENE System on Positive Margin Rates in Breast Conservation Surgery.

NCT05113927

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab

NCT05445778

The Role of Nodal Radiation Therapy in Sentinel Lymph Node Positive Melanoma (MelPORT)

NCT04594187

Compassionate Use (CU) Treatment with glofitamab for patients with relapsed / refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL), transformed Follicular Lymphoma (tFL) or Primary Mediastinal B-Cell Lymphoma (PMBCL)

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT02201992

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission

NCT03267433

Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma

NCT03115333

The National Myelodysplastic Syndromes (MDS) Study

NCT02775383

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

NCT03180268

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

NCT02135042

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

NCT03678025

Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

NCT03860883